Skip NavigationSkip to Content

Knowledge and intention to participate in cervical cancer screening after the human papillomavirus vaccine

  1. Author:
    Price, R. A.
    Koshiol, J.
    Kobrin, S.
    Tiro, J. A.
  2. Author Address

    [Price, RA] NCI, SAIC Frederick Inc, Clin Monitoring Res Program, Frederick, MD 21702 USA [Price, RA] RAND Corp, Frederick, MD 21702 USA [Koshiol, J] NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20852 USA [Kobrin, S] NCI, Appl Canc Screening Res Branch, Div Canc Control & Populat Sci, Bethesda, MD 20852 USA [Tiro, JA] Univ Texas SW Med Ctr Dallas, Div Behav & Commun Sci, Dept Clin Sci, Dallas, TX 75390 USA;Price, RA (reprint author), RAND Corp, 1200 S Hayes St,Room 7139, Arlington, VA 22202 USA;ranhangp@rand.org koshiolj@mail.nih.gov kobrins@mail.nih.gov jtiro@utsouthwestern.edu
    1. Year: 2011
    2. Date: Jun
  1. Journal: Vaccine
    1. 29
    2. 25
    3. Pages: 4238-4243
  2. Type of Article: Article
  3. ISSN: 0264-410X
  1. Abstract:

    Background: If women who receive the human papillomavirus (HPV) vaccine are unduly reassured about the cancer prevention benefits of vaccination, they may choose not to participate in screening, thereby increasing their risk for cervical cancer. This study assesses adult women's knowledge of the need to continue cervical cancer screening after HPV vaccination, describes Pap test intentions of vaccinated young adult women, and evaluates whether knowledge and intentions differ across groups at greatest risk for cervical cancer. Methods: Data were from the 2008 Health Information National Trends Survey (HINTS) and the 2008 National Health Interview Survey (NHIS), which initiated data collection approximately 18 months after the first FDA approval of an HPV vaccine. We calculated associations between independent variables and the outcomes using chi-square tests. Results: Of 1586 female HINTS respondents ages 18 through 74,95.6% knew that HPV-vaccinated women should continue to receive Pap tests. This knowledge did not vary significantly by race/ethnicity, education, income, or healthcare access. Among 1101 female NHIS respondents ages 18-26 who had ever received a Pap test, the proportion (12.7%; n=139) who reported receipt of the HPV vaccine were more likely than those not vaccinated to plan to receive a Pap test within three years (98.1% vs. 92.5%, p < 0.001). Conclusions: US adult women possess high knowledge and intention to participate in Pap testing after HPV vaccination. The vast majority of young adult women who received the HPV vaccine within its first two years on the market intend to participate in cervical cancer screening in the near future. Future studies are needed to examine whether those vaccinated in adolescence will become aware of, and adhere to, screening guidelines as they become eligible. (C) 2011 Elsevier Ltd. All rights reserved.

    See More

External Sources

  1. DOI: 10.1016/j.vaccine.2011.03.076
  2. WOS: 000291777700012

Library Notes

  1. Fiscal Year: FY2010-2011
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel